Gastric autoimmune disorders in patients with chronic hepatitis C before, during the after interferon-alpha therapy
| Autor: | G. Nigro, Silvia Giovanelli, Alessandro Pezzoli, Davide Festi, Antonio Colecchia, M. Francesca Jaboli, Francesco Azzaroli, Carlo Fabbri, A. Miracolo, Enrico Roda, Esterita Accogli, Marco Montagnani, Giuseppe Mazzella, S. Liva |
|---|---|
| Přispěvatelé: | Fabbri C., Jaboli F., Giovanelli S., Azzaroli F., Pezzoli A., Accogli E., Liva S., Nigro G., Miracolo A., Festi D., Colecchia A., Montagnani M., Roda E., Mazzella G. |
| Předmět: |
Adult
Male Autoimmune Gastritis Viral Hepatitis Thyroid Gland Alpha interferon medicine.disease_cause Antiviral Agents Virus Autoimmunity Autoimmune Diseases Helicobacter Infections Autoimmune thyroiditis Parietal Cells Gastric Gastrins medicine Prevalence Humans Prospective Studies Prospective cohort study Gastrin Aged biology Helicobacter pylori business.industry Gastroenterology Interferon-alpha General Medicine Hepatitis C Chronic Middle Aged medicine.disease Treatment Outcome Organ Specificity Gastritis Immunology biology.protein Autoimmune gastritis hepatitis C HCV α-interferon therapy Female Antibody business |
| Zdroj: | Scopus-Elsevier |
| Popis: | To explore the prevalence of autoimmune gastritis in chronic hepatitis C virus (HCV) patients and the influence of alpha-interferon (IFN) treatment on autoimmune gastritis.We performed a prospective study on 189 patients with positive anti-HCV and viral RNA enrolled in a 12-month IFN protocol. We evaluated: a) the baseline prevalence of autoimmune gastritis, b) the impact of IFN treatment on development of biochemical signs of autoimmune gastritis (at 3, 6 and 12 months), c) the evolution after IFN withdrawal (12 months) in terms of anti-gastric-parietal-cell antibodies (APCA), gastrin, anti-thyroid, and anti-non-organ-specific antibodies.APCA positivity and 3-fold gastrin levels were detected in 3 (1.6 %) and 9 (5 %) patients, respectively, at baseline, in 25 (13 %) and 31 (16 %) patients at the end of treatment (both P0.001, vs baseline), and in 7 (4 %) and 14 (7 %) patients 12 months after withdrawal (P=0.002 and P=0.01 respectively, vs baseline; P=not significant vs end of treatment). The development of autoimmune gastritis was strictly associated with the presence of autoimmune thyroiditis (P =0.0001), no relationship was found with other markers of autoimmunity.In HCV patients, IFN frequently precipitates latent autoimmune gastritis, particularly in females. Following our 12-month protocol, the phenomenon generally regressed. Since APCA positivity and high gastrin levels are associated with the presence of antithyroid antibodies, development of autoimmune thyroiditis during IFN treatment may provide a surrogate preliminary indicator of possible autoimmune gastritis to limit the need for invasive examinations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|